<?xml version="1.0" encoding="UTF-8"?>
<p id="p0115">While this manuscript was under peer-review, a study assessing known protease inhibitors for their anti-SARS-CoV-2 M
 <sup>pro</sup> activity was published.
 <xref rid="b0510" ref-type="bibr">
  <sup>102</sup>
 </xref> Amongst the compounds that displayed M
 <sup>pro</sup> inhibition and reduction of cytopathic effect were the α-ketoamides boceprevir (
 <italic>K</italic>
 <sub>i</sub> = 1.18 μΜ, EC
 <sub>50</sub> = 1.31 μM) and calpain inhibitor XII (
 <italic>K</italic>
 <sub>i</sub> = 0.13 μΜ, EC
 <sub>50</sub> = 0.49 μM), the peptide-aldehyde calpain inhibitor II (
 <italic>K</italic>
 <sub>i</sub> = 0.40 μΜ, EC
 <sub>50</sub> = 2.07 μM) and the sulfonate-featured peptide GC-376 (
 <italic>k</italic>
 <sub>2</sub>/
 <italic>K</italic>
 <sub>i</sub> = 40,800 M
 <sup>−1</sup> s
 <sup>−1</sup>, EC
 <sub>50</sub> = 3.37 μM). A crystal structure of SARS-CoV-2 M
 <sup>pro</sup> in complex with GC-376 was also reported (PDB: 6WTT).
</p>
